Infant Bacterial Therapeutics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Infant Bacterial Therapeutics
Access all reports
Infant Bacterial Therapeutics AB, a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company focuses on late onset neonatal infection, a disease caused by an imbalance in the infant’s gut microbiota. Its lead drug candidate is IBP-9414 is being developed for the treatment of lactobacillus plantarum, enterococcus faecium and escherichia coli infections in preterm infants. The company was formerly known as Enterome AB and changed its name to Infant Bacterial Therapeutics AB in August 2012. Infant Bacterial Therapeutics AB is based in Stockholm, Sweden. As of March 4, 2015, Infant Bacterial Therapeutics AB operates as a subsidiary of Tim Medical Holdings Limited.
Latest articles
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Puig's 2024 IPO: Paco Rabanne, Jean Paul Gaultier, and Beyond
Explore Puig's journey from its 1914 inception to a 2024 IPO, showcasing its growth, strategic acquisitions, and impact in the beauty and fashion industry.
15 Apr 2024
Alphabet's Unstoppable Rise: From Stanford to Global Tech Leader
Discover Alphabet's rise from a university project to a global tech leader, highlighting its growth, diversification, and visionary leadership.
15 Apr 2024
Ticker symbol
Country
🇸🇪 Sweden